

Présentations orales

Cancers de sein

- Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort. B. Pistilli, A. Paci, S. Michiels, A. Ferreira, V. Poinignon, P. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, C. Jouannaud, C. Levy, S. Everhard, P. Arveux, A. Partridge, S. Delalogue, F. André, I. Vaz-Luis.
- Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: a randomised, open-label trial. E. Le Rhun, A. Mailliez, J. Wallet, I. Rodrigues, T. Boulanger, I. Desmoulins, J. Barriere, M. Fabbro, S. Taillibert, C. Andre, M.C. Le Deley, M. Weller, J. Bonneterre

Sarcomes

- Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. J.-Y. Blay, M. Toulmonde, N. Penel, O. Mir, C. Chevreau, P. Anract, E. Bompas, M. Rios, N. Firmin, A. Italiano, S. Piperno-Neumann, J.-E. Kurtz, F. Duffaud, P. Rosset, F. Bertucci, C. Perrin, C. Chemin, F. Ducimetiere, F. Gouin, A. Le Cesne
- Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study. A. Italiano, N. Penel, M. Toulmonde, E. Bompas, S. Piperno-Neumann, M. Pulido, N. Entz-Werle, A. Le Cesne, C. Chevreau, F. Duffaud, I. Ray-Coquard, C. Bellera, S. Mathoulin-Pelissier, J.-Y. Blay

Ovaires

- Alienor/ENGOT-ov7 randomized trial exploring weekly Paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian Sex Cord tumors (SCT) in relapse. I. Ray-Coquard, P. Harter, D. Lorusso, C. Dalban, I. Vergote, K. Fujiwara, L. Gladiëff, H.-J. Lueck, A. Floquet, A.F. Lesoin, A. Schnelzer, S. Pignata, F. Selle, J. Sehouli, F. Brocard, G. Mangili, P. Pautier, U. De Giorgi, M. Provansal, P.-E. Heudel

Toutes tumeurs solides (phase 1)

- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF- β , in patients (pts) with advanced SCCHN: results from a phase 1 cohort. B.C. Cho, A. Daste, A. Ravaud, S. Salas, N. Isambert, E. McClay, A. Awada, C. Borel, J. Gulley, L. Ojalvo, C. Helwig, P.A. Rolfe, N. Penel

Communications affichées

Seins

- PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 /

UNICANCER UC-0140/1207). J. Huober, P. Weder, C. Veyret, B. Thürlimann, A. Xyrafas, L. Vanlemmens, S. Guiu, E. Brain, J. Grenier, F. Dalenc, C. Levy, A.M. Savoye, A. Müller, V. MembrezAntonioli, M.A. Gerard, J. Lemonnier, H. Hawle, E. Boven, H. Bonnefoi

- Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program. J. Sirieix, J. Fraisse, S. Mathoulin-Pelissier, M. Leheurteur, L. Vanlemmens, C. Jouannaud, V. Dieras, C. Levy, F. Dalenc, M.-A. Mouret-Reynier, T. Petit, B. Coudert, E. Brain, B. Pistilli, J.-M. Ferrero, A. Gonçalves, L. Uwer, S. Gourgou, J.- S. Frenel
- Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2- negative, invasive lobular carcinoma of the breast A. De Nonneville, C. Jauffret, A. Gonçalves, J.-M. Classe, M. Cohen, F. Reyal, C. Mazouni, M.-P. Chauvet, N. Chopin, P.-E. Colombo, E. Jouve, E. Darai, R. Rouzier, C. Coutant, P. Gimbergues, A.-S. Azuar, C. Tunon de Lara, E. Lambaudie, G. Houvenaeghel
- Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node Negative Breast Carcinomas A. De Nonneville, A. Gonçalves, J.-M. Boher, J.-M. Classe, M. Cohen, P.-E. Colombo, F. Reyal, M.-P. Chauvet, E. Jouve, E. Darai, G. Blache, C. Coutant, P. Gimbergues, C. Mazouni, R. Rouzier, R. Villet, P. Crochet, A.-S. Azuar, E. Lambaudie, G. Houvenaeghel
- Early breast cancer classified as intermediate risk by the Prosigna assay: Characteristics and treatment strategy N. Hajjaji, Y.M. Robin, D. Bertin, J. Bonneterre
- Benefits of physical activity and sport integrated into the care pathway of oncology patient L. Vanlemmens, H. Mocaer, T. Ginsbourger, J.M. Descotes, N. Masselin, H. Deroubaix, C. Fabre, J. Devriendt, T. Bouillet, E. Lartigau
- Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC). A. Di Meglio, M. El-Mouhebb, S. Michiels, D. Carene, S. Everhard, A.L. Martin, P. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, P.Arveux, S. Delalogue, P. Ganz, F. André, A. Partridge, L. Jones, I. Vaz-Luis
- Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). A. Di Meglio, M. El-Mouhebb, S. Michiels, L. Jones, E. Martin, M. Matias, A.E. Lohmann Palhares, F. Joly, L. Vanlemmens, S. Everhard, A.L. Martin, J. Lemonnier, P. Arveux, P. Cottu, C. Coutant, L. Del Mastro, A. Partridge, F. André, J. Ligibel, I. Vaz-Luis
- Impact of breast cancer molecular subtypes on the occurrence, kinetics and prognosis of central nervous system metastases in a large multicenter cohort. W. Jacot, G. Louvel, A. Darlix, J. Fraisse, E. Brain, M. Debled, M.A. Mouret Reynier, A. Goncalves, F. Dalenc, P. Augereau, J.-M. Ferrero, C. Levy, J.-D. Fumet, C. Jouannaud, C. Veyret, V. Dieras, M. Robain, C. Courtinard, D. Pasquier, T. Bachelot

Tête et cou

- TOPNIVO - A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): first results on behalf of the Unicancer Head&Neck Group and the GORTEC. C. Even, A. Daste, E. Saada-Bouzid, J. Fayette, M.-C. Kaminsky-Forrett, S. Zanetta, A. Prevost, G. Lefebvre, C. Borel, D. Cupissol, F. Huguet, J.-P. Delord, N. Baste Rotllan, J. Delaye, I. Jallut, N. Vintonenko, J. Bourhis, J. Guigay, M. Texier, A. Auperin

- Elderly patients with locally advanced head and neck squamous cell carcinoma treated with NBTXR3 nanoparticles activated by radiotherapy: a phase I trial. C. Le Tourneau, V. Calugaru, V. Moreno, X. Mirabel, B. Dodger, E. Calvo, T. Jouffroy, J. Rodriguez, A. Chilles, M. Yemi, C. Hoffmann
- Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J. Fayette, G. Lefebvre, M. Posner, J. Bauman, S. Salas, C. Even, E. Saada-Bouزيد, T. Seiwert, D. Colevas, F. Calmels, R. Zerbib, A. Boyer Chammard, R. Cohen

Appareil digestif

- HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma A. Bernard-Tessier, E. Jeannot, D. Guenat, M. Michel, C. Proudhon, A. VincentSalomon, I. Bièche, J.-Y. Pierga, B. Buecher, E. Francois, S. Kim, T. André, M. Jary, V. Vendrely, E. Samalin, F. El Hajbi, N. Baba-Hamed, A. Meurisse, F.-C. Bidard, C. Borg
- PRODIGE 29-UCGI 26(NEOPAN): A Randomised trial of chemotherapy with Folfirinor or gemcitabine in locally advanced pancreatic carcinoma (PC). M. Ducreux, R. Desgrippes, M. Texier, F. Di Fiore, P. Vanelslander, O. Capitain, R. Guimbaud, J. Forestier, F. El Hajbi, P. Follana, A. Parzy, N. Baba Hamed, Y. Rinaldi, T. Brotelle, J.-P. Pignon, C. Jouffroy, L. Dahan, O. Bouche

Poumons

- Bevacizumab as first-line treatment in advanced non-squamous nonsmall cell lung cancer (NSCLC) in patients aged over 65 years in France. Final results of the AVANTAGE study. F. Lionel, D. Perol, P.-J. Souquet, H. Le Caer, E. Dansin, C. Audigier Valette, J.-L. Mouysset, M.L. Uffredi, M. Ionescu-Goga, K. Veerabudun, Y. Lelarge, E. Fabre-Guillevin
- Clinical characteristics and outcomes of non-small cell lung cancer (NSCLC) patients harboring MET exon 14 splice sites mutations. P. Jamme, F. Escande, C. Descarpentries, M.C. Copin, E. Dansin, T. Vanparis, D. Tulasne, S. Baldacci, Z. Kherrouche, A. Cortot

Appareil urinaire

- Neuroendocrine carcinoma of the urinary bladder: a large analysis of the French GETUG consortium. M. Sroussi, M. Lorcet, M. Tardy, M. Guerin, F. Estrade, R. Delva, P. Barthelemy, P.Lavaud, Y. Neuzillet, N. Penel, N. Houede, D. Pouessel, E. Mussat, M. Gross-Goupil, H. Gauthier, A. Gobert, O. Huillard, Y. Allory, R.-T. Elaidi, S. Oudard

Ovaires

- Bcl-2 proteins expression and response to Navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC). P.E. Brachet, F. Joly Lobbedez, M. Fabbro, A. Leary, J. Medioni, P. Follana, A.F. Lesoin, J.-S. Frenel, S. Abadie Lacourtoisie, A. Floquet, L. Gladiéff, B. You, C. Gavaille, E. Kalbacher, M. Briand, P.A. Just, C. Blanc-Fournier, F. Giffard, B. Clarisse, L. Poulain